TipRanks
Advertisement
Advertisement

DE:E08A Stock Latest News

Craig-Hallum sees potential for confusion after CMS fee schedule
The FlyCraig-Hallum sees potential for confusion after CMS fee schedule
11d ago
GH
NEO
Exagen transferred with Buy rating at B. Riley
PremiumThe Fly
Exagen transferred with Buy rating at B. Riley
22d ago
XGN
Exagen participates in a conference call with Craig-Hallum
PremiumThe Fly
Exagen participates in a conference call with Craig-Hallum
1M ago
XGN
Exagen price target raised to $9 from $8 at BTIG
PremiumThe Fly
Exagen price target raised to $9 from $8 at BTIG
2M ago
XGN
Exagen price target raised to $12 from $8 at B. Riley
PremiumThe Fly
Exagen price target raised to $12 from $8 at B. Riley
2M ago
XGN
Exagen price target raised to $10 from $8 at TD Cowen
PremiumThe FlyExagen price target raised to $10 from $8 at TD Cowen
2M ago
XGN
Exagen price target raised to $9 from $8 at Canaccord
Premium
The Fly
Exagen price target raised to $9 from $8 at Canaccord
2M ago
XGN
Exagen Earns Buy Rating as Strong Q2 Performance, Lower Cash Risk, and Growth Pipeline Drive Price Target Increase to $10
Premium
Ratings
Exagen Earns Buy Rating as Strong Q2 Performance, Lower Cash Risk, and Growth Pipeline Drive Price Target Increase to $10
2M ago
XGN
Exagen Earnings Call Highlights Record Growth And Margin Gains
PremiumCompany Announcements
Exagen Earnings Call Highlights Record Growth And Margin Gains
2M ago
XGN
Exagen raises FY26 revenue view to $72M-$75M from $70M-$73M
PremiumThe Fly
Exagen raises FY26 revenue view to $72M-$75M from $70M-$73M
2M ago
XGN
Exagen reports Q2 EPS (13c), consensus (17c)
PremiumThe Fly
Exagen reports Q2 EPS (13c), consensus (17c)
2M ago
XGN
XGN Upcoming Earnings Report: What to Expect?
PremiumPre-Earnings
XGN Upcoming Earnings Report: What to Expect?
2M ago
XGN
Spero Therapeutics appoints Debra Jeske Zack as chief medical officer
PremiumThe FlySpero Therapeutics appoints Debra Jeske Zack as chief medical officer
2M ago
XGN
SPRO
Roth starts Exagen at Buy, notes biomarker testing outperformance
Premium
The Fly
Roth starts Exagen at Buy, notes biomarker testing outperformance
3M ago
XGN
Exagen initiated with a Buy at Roth Capital
Premium
The Fly
Exagen initiated with a Buy at Roth Capital
3M ago
XGN
Exagen Shareholders Approve Directors, Auditor and Pay Package
PremiumCompany Announcements
Exagen Shareholders Approve Directors, Auditor and Pay Package
4M ago
8K
XGN
Exagen Earnings Call Highlights Growth Amid Headwinds
PremiumCompany Announcements
Exagen Earnings Call Highlights Growth Amid Headwinds
5M ago
XGN
Exagen Earnings Call Highlights Growth Amid Key Risks
PremiumCompany Announcements
Exagen Earnings Call Highlights Growth Amid Key Risks
5M ago
XGN
Exagen Wins Buy Rating on Strong Q1 Beat, Improving Fundamentals and Clear Path to EBITDA Breakeven
PremiumRatings
Exagen Wins Buy Rating on Strong Q1 Beat, Improving Fundamentals and Clear Path to EBITDA Breakeven
5M ago
XGN
Exagen: Buy Rating Reiterated as Strong Execution and Growth Outlook Support Unchanged $8 Price Target
PremiumRatingsExagen: Buy Rating Reiterated as Strong Execution and Growth Outlook Support Unchanged $8 Price Target
5M ago
XGN
Exagen price target lowered to $8 from $9 at BTIG
Premium
The Fly
Exagen price target lowered to $8 from $9 at BTIG
5M ago
XGN
Exagen’s Risk Profile Remains Unchanged: Stable Yet Persistent Exposures Keep Investors on Alert
Premium
Company Announcements
Exagen’s Risk Profile Remains Unchanged: Stable Yet Persistent Exposures Keep Investors on Alert
5M ago
XGN

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >